NASDAQ:FTSV

Forty Seven (FTSV) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$95.51
$95.51
50-Day Range
$95.51
$95.51
52-Week Range
$5.53
$95.51
Volume
N/A
Average Volume
1.61 million shs
Market Capitalization
$4.60 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
FTSV stock logo

About Forty Seven Stock (NASDAQ:FTSV)

Forty Seven Inc., a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; FSI-189, an antibody that binds to SIRPa; and FSI-174, an anti-cKIT antibody. Forty Seven Inc. has a collaboration agreement with Genentech to include third clinical trial in non-Hodgkin's lymphoma. The company was formerly known as CD47 Sciences, Inc. Forty Seven Inc. was incorporated in 2014 and is headquartered in Menlo Park, California.

FTSV Stock News Headlines

49ers sign veteran tight end
Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share
The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty.
Formula Systems (1985) Ltd ADR FORTY
Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share
The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty.
Week one: seven-day detox
Meet our Forty Under 40 winners
FTSV_old Historical Data
See More Headlines
Receive FTSV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Forty Seven and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/12/2019
Today
4/25/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:FTSV
CIK
N/A
Fax
N/A
Employees
57
Year Founded
N/A

Profitability

Net Income
$-87,620,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$15.68 million
Book Value
$7.52 per share

Miscellaneous

Free Float
N/A
Market Cap
$4.60 billion
Optionable
Not Optionable
Beta
0.40
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Mark A. McCamish (Age 66)
    Pres, CEO & Director
  • Dr. Craig S. Gibbs (Age 56)
    Chief Bus. Officer
  • Dr. Chris H. Takimoto M.D. (Age 60)
    Ph.D., Chief Medical Officer
  • Mr. Mark Chao
    Founder & VP of Clinical Devel.
  • Mr. Jens-Peter Volkmer
    Founder and VP of Research & Early Devel.

FTSV Stock Analysis - Frequently Asked Questions

How were Forty Seven's earnings last quarter?

Forty Seven Inc (NASDAQ:FTSV) issued its earnings results on Tuesday, November, 12th. The company reported ($0.38) earnings per share for the quarter, meeting the consensus estimate of ($0.38). The firm earned $15.68 million during the quarter, compared to analysts' expectations of $15.80 million.

What other stocks do shareholders of Forty Seven own?
When did Forty Seven IPO?

Forty Seven (FTSV) raised $100 million in an IPO on Thursday, June 28th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley and Credit Suisse served as the underwriters for the IPO and Canaccord Genuity, BTIG and Oppenheimer were co-managers.

This page (NASDAQ:FTSV) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners